EMA finds no evidence linking viral vector in Zynteglo to blood cancer

View source ↗

Summary

The EMA reports no evidence that the viral vector used in Zynteglo is linked to blood cancer, though continued monitoring is advised.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Sickle Cell Disease

Drugs mentioned

• Zynteglo (luspogene nepogene)